Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087

被引：0
|
作者：
Abraham, WT
Suresh, DP
Wagoner, LE
Haas, GJ
McCord, J
Rydzinski, S
Nelson, CB
Bakker-Arkema, RG
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Parke Davis Pharm Res, Ann Arbor, MI USA
来源：
CIRCULATION | 1999年 / 100卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1562
引用
收藏
页码：299 / 299
页数：1
相关论文
共 50 条
  • [1] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [2] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [3] Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
    Yatsu, T
    Tomura, Y
    Tahara, A
    Wada, K
    Kusayama, T
    Tsukada, J
    Tokioka, T
    Uchida, W
    Inagaki, O
    Iizumi, Y
    Tanaka, A
    Honda, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (03) : 239 - 246
  • [4] Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, MM
    Thomas, I
    Ghali, JK
    Selaru, P
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2000, 102 (18) : 593 - 593
  • [5] Haemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist, in patients with advanced heart failure
    Udelson, J
    Smith, WB
    Hendrix, G
    Painchaud, C
    Ghazzi, MM
    Thomas, I
    Ghali, J
    Selaru, P
    Pressler, M
    Konstam, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [6] Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist
    Abraham, W
    Koren, M
    Bichet, DG
    Verbalis, JG
    Klapholz, M
    Selaru, P
    Bakker-Arkema, RG
    Rummel, SA
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [7] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    Burnier, M
    Fricker, AF
    Hayoz, D
    Nussberger, J
    Brunner, HR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (09) : 633 - 637
  • [8] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    M. Burnier
    A. F. Fricker
    D. Hayoz
    J. Nussberger
    H. R. Brunner
    European Journal of Clinical Pharmacology, 1999, 55 : 633 - 637
  • [9] Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V(1A) and V2 receptor antagonist
    Tahara A.
    Saito M.
    Sugimoto T.
    Tomura Y.
    Wada K.
    Kusayama T.
    Tsukada J.
    Ishii N.
    Yatsu T.
    Uchida W.
    Tanaka A.
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 357 (1) : 63 - 69
  • [10] Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Artur Giełdoń
    Rajmund Kaźmierkiewicz
    Rafał Ślusarz
    Jerzy Ciarkowski
    Journal of Computer-Aided Molecular Design, 2001, 15 : 1085 - 1104
12345